^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Ishida N, Miura N, Yoshioka S, Kawakita M (Apr 1997). "Molecular cloning and characterization of a novel isoform of the human UDP-galactose transporter, and of related complementary DNAs belonging to the nucleotide-sugar transporter gene family". J Biochem. 120 (6): 1074–8. doi:10.1093/oxfordjournals.jbchem.a021523. PMID9010752.
^Ishida N, Ito M, Yoshioka S, Sun-Wada GH, Kawakita M (Sep 1998). "Functional expression of human golgi CMP-sialic acid transporter in the Golgi complex of a transporter-deficient Chinese hamster ovary cell mutant". J Biochem. 124 (1): 171–8. doi:10.1093/oxfordjournals.jbchem.a022076. PMID9644260.
Wahlberg JE (1976). "Sensitization and testing of guinea pigs with nickel sulfate". Dermatologica. 152 (6): 321–30. doi:10.1159/000251278. PMID964426.
Harvey BE, Thomas P (1993). "Inhibition of CMP-sialic acid transport in human liver and colorectal cancer cell lines by a sialic acid nucleoside conjugate (KI-8110)". Biochem. Biophys. Res. Commun. 190 (2): 571–5. doi:10.1006/bbrc.1993.1086. PMID8427599.
Lennon G, Auffray C, Polymeropoulos M, Soares MB (1996). "The I.M.A.G.E. Consortium: an integrated molecular analysis of genomes and their expression". Genomics. 33 (1): 151–2. doi:10.1006/geno.1996.0177. PMID8617505.
Martinez-Duncker I, Dupré T, Piller V, et al. (2005). "Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter". Blood. 105 (7): 2671–6. doi:10.1182/blood-2004-09-3509. PMID15576474. S2CID13582151.
Misaki R, Fujiyama K, Seki T (2006). "Expression of human CMP-N-acetylneuraminic acid synthetase and CMP-sialic acid transporter in tobacco suspension-cultured cell". Biochem. Biophys. Res. Commun. 339 (4): 1184–9. doi:10.1016/j.bbrc.2005.11.130. PMID16343442.